Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Redirecting the revolution: new developments in drug development for psychiatry.

Brady LS, Potter WZ, Gordon JA.

Expert Opin Drug Discov. 2019 Dec;14(12):1213-1219. doi: 10.1080/17460441.2019.1666102. Epub 2019 Sep 23. No abstract available.

PMID:
31545131
2.

The FNIH Biomarkers Consortium embraces the BEST.

Menetski JP, Austin CP, Brady LS, Eakin G, Leptak C, Meltzer A, Wagner JA.

Nat Rev Drug Discov. 2019 Jul;18(8):567-568. doi: 10.1038/d41573-019-00015-w. No abstract available.

PMID:
31367046
3.

Athina Markou's contributions to treatment development for mental illnesses: a perspective.

Winsky L, Brady LS.

Psychopharmacology (Berl). 2017 May;234(9-10):1645-1647. doi: 10.1007/s00213-016-4485-5. Epub 2016 Nov 24. No abstract available.

PMID:
27882396
4.

Medicines for the mind: policy-based "pull" incentives for creating breakthrough CNS drugs.

Choi DW, Armitage R, Brady LS, Coetzee T, Fisher W, Hyman S, Pande A, Paul S, Potter W, Roin B, Sherer T.

Neuron. 2014 Nov 5;84(3):554-63. doi: 10.1016/j.neuron.2014.10.027. Epub 2014 Nov 5. Review.

5.

Current drug development for antidepressants and ideas addressing downstream glutamate: the ketamine example.

Potter WZ, Brady LS.

CNS Spectr. 2014 Apr;19(2):112-4. doi: 10.1017/S1092852914000029. Epub 2014 Feb 25. No abstract available.

PMID:
24565466
6.

Proteomic biomarkers for brain disorders: technical considerations and challenges.

Brady LS, Potter WZ.

Neuropsychopharmacology. 2014 Jan;39(1):252. doi: 10.1038/npp.2013.202. No abstract available.

7.

Public-private partnerships to revitalize psychiatric drug discovery.

Brady LS, Potter WZ.

Expert Opin Drug Discov. 2014 Jan;9(1):1-8. doi: 10.1517/17460441.2014.867944. Epub 2013 Dec 6.

PMID:
24308355
8.

Assessing biomarkers for brain diseases: progress and gaps.

Brady LS.

Genome Med. 2013 Mar 20;5(3):23. doi: 10.1186/gm427. eCollection 2013.

9.

Partnering for therapeutics discovery.

Colvis CM, Devaney S, Brady LS, Hudson KL.

Clin Pharmacol Ther. 2013 Jan;93(1):24-5. doi: 10.1038/clpt.2012.188. Epub 2012 Nov 28. Review. No abstract available.

PMID:
23187876
10.

Translating discoveries into medicine: psychiatric drug development in 2011.

Brady LS, Insel TR.

Neuropsychopharmacology. 2012 Jan;37(1):281-3. doi: 10.1038/npp.2011.106. No abstract available.

11.

NIMH initiatives to facilitate collaborations among industry, academia, and government for the discovery and clinical testing of novel models and drugs for psychiatric disorders.

Brady LS, Winsky L, Goodman W, Oliveri ME, Stover E.

Neuropsychopharmacology. 2009 Jan;34(1):229-43. doi: 10.1038/npp.2008.125. Epub 2008 Sep 17. Review.

12.

Grand challenges for psychiatric drug discovery: a perspective.

Brady LS, Giffin RB, Woodcock J, Cassell GH, Holmes EW.

Neuropsychopharmacology. 2008 Aug;33(9):2047. doi: 10.1038/npp.2008.54. No abstract available.

13.

Building a pharmacological lexicon: small molecule discovery in academia.

Lazo JS, Brady LS, Dingledine R.

Mol Pharmacol. 2007 Jul;72(1):1-7. Epub 2007 Apr 3. Review.

PMID:
17405872
14.

NIH Molecular Libraries Initiative.

Austin CP, Brady LS, Insel TR, Collins FS.

Science. 2004 Nov 12;306(5699):1138-9. No abstract available.

PMID:
15542455
15.

Dimerization of G-protein coupled receptors.

Devi LA, Brady LS.

Neuropsychopharmacology. 2000 Oct;23(4 Suppl):S3-4. Review. No abstract available.

16.
17.

Region-specific up-regulation of opioid receptor binding in enkephalin knockout mice.

Brady LS, Herkenham M, Rothman RB, Partilla JS, K├Ânig M, Zimmer AM, Zimmer A.

Brain Res Mol Brain Res. 1999 May 7;68(1-2):193-7.

PMID:
10320798
18.

Age and gender influence basal and stress-modulated hypothalamic-pituitary-thyroidal function in Fischer 344/N rats.

Cizza G, Brady LS, Esclapes ME, Blackman MR, Gold PW, Chrousos GP.

Neuroendocrinology. 1996 Dec;64(6):440-8.

PMID:
8990077
20.

Opioid receptor ligand binding in the human striatum: II. Heterogeneous distribution of kappa opioid receptor labeled with [3H]bremazocine.

Vonkeman HE, Voorn P, Brady LS, Berendse HW, Richfield EK.

J Comp Neurol. 1996 Oct 14;374(2):223-9.

PMID:
8906495
21.
23.

Stress-induced inhibition of the hypothalamic-pituitary-thyroid axis is attenuated in the aged Fischer 344/N male rat.

Cizza G, Brady LS, Pacak K, Blackman MR, Gold PW, Chrousos GP.

Neuroendocrinology. 1995 Nov;62(5):506-13.

PMID:
8559282
24.

Chronic social stress increases levels of preprogalanin mRNA in the rat locus coeruleus.

Holmes PV, Blanchard DC, Blanchard RJ, Brady LS, Crawley JN.

Pharmacol Biochem Behav. 1995 Apr;50(4):655-60.

PMID:
7542391
25.

Decreased stress responsivity of central and peripheral catecholaminergic systems in aged 344/N Fischer rats.

Cizza G, Pacak K, Kvetnansky R, Palkovits M, Goldstein DS, Brady LS, Fukuhara K, Bergamini E, Kopin IJ, Blackman MR, et al.

J Clin Invest. 1995 Mar;95(3):1217-24.

26.

Evidence for two neurochemical divisions in the human nucleus accumbens.

Voorn P, Brady LS, Schotte A, Berendse HW, Richfield EK.

Eur J Neurosci. 1994 Dec 1;6(12):1913-6.

PMID:
7704301
28.

Systemic interleukin-1 induces early and late patterns of c-fos mRNA expression in brain.

Brady LS, Lynn AB, Herkenham M, Gottesfeld Z.

J Neurosci. 1994 Aug;14(8):4951-64.

29.

Regulation of HSP90 and corticosteroid receptor mRNA by corticosterone levels in vivo.

Patchev VK, Brady LS, Karl M, Chrousos GP.

Mol Cell Endocrinol. 1994 Jul;103(1-2):57-64.

PMID:
7958398
30.

Male Fischer 344/N rats show a progressive central impairment of the hypothalamic-pituitary-adrenal axis with advancing age.

Cizza G, Calogero AE, Brady LS, Bagdy G, Bergamini E, Blackman MR, Chrousos GP, Gold PW.

Endocrinology. 1994 Apr;134(4):1611-20.

PMID:
8137722
31.

Hypothalamic lesions increase levels of neuropeptide Y mRNA in the arcuate nucleus of mice.

Young JK, McKenzie JC, Brady LS, Herkenham M.

Neurosci Lett. 1994 Jan 3;165(1-2):13-7.

PMID:
8015714
32.

1,1'-Ethylidenebis[L-tryptophan], a contaminant implicated in L-tryptophan eosinophilia myalgia syndrome, suppresses mRNA expression of hypothalamic corticotropin-releasing hormone in Lewis (LEW/N) rat brain.

Brady LS, Page SW, Thomas FS, Rader JL, Lynn AB, Misiewicz-Poltorak B, Zelazowski E, Crofford LJ, Zelazowski P, Smith C, et al.

Neuroimmunomodulation. 1994 Jan;1(1):59-65.

PMID:
8528886
33.

Stress, antidepressant drugs, and the locus coeruleus.

Brady LS.

Brain Res Bull. 1994;35(5-6):545-56. Review.

PMID:
7859112
35.

Increased arginine vasopressin secretion may participate in the enhanced susceptibility of Lewis rats to inflammatory disease.

Patchev VK, Mastorakos G, Brady LS, Redwine J, Wilder RL, Chrousos GP.

Neuroendocrinology. 1993 Jul;58(1):106-10.

PMID:
8264843
36.

Repeated immobilization stress alters tyrosine hydroxylase, corticotropin-releasing hormone and corticosteroid receptor messenger ribonucleic Acid levels in rat brain.

Mamalaki E, Kvetnansky R, Brady LS, Gold PW, Herkenham M.

J Neuroendocrinol. 1992 Dec;4(6):689-99. doi: 10.1111/j.1365-2826.1992.tb00220.x.

PMID:
21554656
37.

Central hypothyroidism is associated with advanced age in male Fischer 344/N rats: in vivo and in vitro studies.

Cizza G, Brady LS, Calogero AE, Bagdy G, Lynn AB, Kling MA, Blackman MR, Chrousos GP, Gold PW.

Endocrinology. 1992 Dec;131(6):2672-80.

PMID:
1446609
38.

Interaction of opioid peptides and other drugs with multiple kappa receptors in rat and human brain. Evidence for species differences.

Rothman RB, Bykov V, Xue BG, Xu H, De Costa BR, Jacobson AE, Rice KC, Kleinman JE, Brady LS.

Peptides. 1992 Sep-Oct;13(5):977-87.

PMID:
1336192
39.
40.

Intrahippocampal colchicine alters hypothalamic corticotropin-releasing hormone and hippocampal steroid receptor mRNA in rat brain.

Brady LS, Lynn AB, Whitfield HJ Jr, Kim H, Herkenham M.

Neuroendocrinology. 1992 Feb;55(2):121-33.

PMID:
1320216
41.

Effects of stress and adrenalectomy on tyrosine hydroxylase mRNA levels in the locus ceruleus by in situ hybridization.

Smith MA, Brady LS, Glowa J, Gold PW, Herkenham M.

Brain Res. 1991 Mar 22;544(1):26-32.

PMID:
1677301
43.

L-tryptophan implicated in human eosinophilia-myalgia syndrome causes fasciitis and perimyositis in the Lewis rat.

Crofford LJ, Rader JI, Dalakas MC, Hill RH Jr, Page SW, Needham LL, Brady LS, Heyes MP, Wilder RL, Gold PW, et al.

J Clin Invest. 1990 Nov;86(5):1757-63.

44.

Altered expression of hypothalamic neuropeptide mRNAs in food-restricted and food-deprived rats.

Brady LS, Smith MA, Gold PW, Herkenham M.

Neuroendocrinology. 1990 Nov;52(5):441-7.

PMID:
2177853
45.

Optimization of cRNA probe in situ hybridization methodology for localization of glucocorticoid receptor mRNA in rat brain: a detailed protocol.

Whitfield HJ Jr, Brady LS, Smith MA, Mamalaki E, Fox RJ, Herkenham M.

Cell Mol Neurobiol. 1990 Mar;10(1):145-57.

PMID:
2334945
46.

Interaction of endogenous opioid peptides and other drugs with four kappa opioid binding sites in guinea pig brain.

Rothman RB, Bykov V, de Costa BR, Jacobson AE, Rice KC, Brady LS.

Peptides. 1990 Mar-Apr;11(2):311-31.

PMID:
2162533
47.

Evidence for four opioid kappa binding sites in guinea pig brain.

Rothman RB, Bykov V, de Costa BR, Jacobson AE, Rice KC, Brady LS.

Prog Clin Biol Res. 1990;328:9-12. No abstract available.

PMID:
2154826
48.

Regulation of carboxypeptidase H gene expression in magnocellular neurons: response to osmotic stimulation.

Bondy CA, Whitnall MH, Brady LS.

Mol Endocrinol. 1989 Dec;3(12):2086-92.

PMID:
2628743
49.

Coexisting peptides in hypothalamic neuroendocrine systems: some functional implications.

Bondy CA, Whitnall MH, Brady LS, Gainer H.

Cell Mol Neurobiol. 1989 Dec;9(4):427-46. Review.

PMID:
2575930
50.

Cholecystokinin evokes secretion of oxytocin and vasopressin from rat neural lobe independent of external calcium.

Bondy CA, Jensen RT, Brady LS, Gainer H.

Proc Natl Acad Sci U S A. 1989 Jul;86(13):5198-201.

Supplemental Content

Loading ...
Support Center